Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b study of vedolizumab plus upadacitinib versus vedolizumab plus placebo for induction in moderately to severely active Crohn's disease, followed by vedolizumab maintenance
MOH_2025-04-10_014023Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Apr 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Vedolizumab + upadacitinib induction with Vedolizumab + placebo induction (2 arms). Started Apr 2025; status: recruiting.
02
Drugs
vedolizumabupadacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2025-04-10_014023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-04-10_014023.